Navigation Links
Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
Date:1/4/2011

NATICK, Mass., Jan. 4, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today issued the following statement from Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, on an article that was published online today by the Journal of the American Medical Association.  The article reported on a study that found that about 20 percent of patients who received an implantable cardioverter defibrillator (ICD) did not meet evidence-based guidelines for receipt of one.

"Guidelines represent consensus from the scientific community that a given procedure or treatment is beneficial, useful and effective.  Boston Scientific is proud to have sponsored many of the clinical trials that provided the scientific foundation for the guidelines referenced in the JAMA article.

"However, it is important to place these results in their appropriate clinical context.  Sudden cardiac arrest (SCA) is the most common cause of death in the U.S.  About 460,000 Americans die each year from SCA; that is more than lung cancer, breast cancer and HIV-related diseases combined.  Currently, more than a million patients are eligible for an ICD, but only a small percentage of patients actually receive the life-saving device.  In fact, previous studies show that ICDs are used in only 20-40 percent of indicated patients in the U.S.

"Dr. Sana Al-Khatib has made important contributions to addressing the under-utilization of device therapies for the prevention of SCA.  She played a key role in organizing the Sudden Cardiac Arrest Thought Leadership Alliance, a think tank on the issue that met in December 2009.  That meeting led to a recent publication on the issue: "Addressing disparities in sudden cardiac arrest care and the under-utilization of effective therapies."  Its major conclusion was: "Despite overwhelming clinical trial evidence, expert opinion, national guidelines, and a vast array of educational conferences, evidence-based, life-prolonging drug and device therapies continue to be under-utilized, with significant disparities in SCA care and use of ICDs in vulnerable populations, including blacks, women and the elderly."

"It is interesting to note that three of four cases cited in the JAMA article were outside the guidelines solely on the basis of timing, and that many of these patients would have qualified within a matter of weeks or months.

"ICD and cardiac resynchronization therapy defibrillator (CRT-D) therapies have been shown to be cost effective in the MADIT II, COMPANION and SCD-HeFT clinical trial patient populations.  In addition, long-term data from the MADIT II study showed that the life-saving benefits of ICD therapy were sustained at eight years (34 percent relative reduction in the risk of death).  In that trial, one life was saved for every eight patients who received an ICD.

"While ICDs are at times used outside the guidelines, the more fundamental problem is that on the whole, this life-saving therapy is under-utilized, rather than over-utilized."  

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com. CONTACT:

Paul Donovan508-650-8541 (office)508-667-5165 (mobile)Media RelationsBoston Scientific CorporationLarry Neumann508-650-8696 (office)Investor RelationsBoston Scientific CorporationSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporation
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cannabis Science Files Preliminary 14c Information Statement, the Action is to Create a New Class of Common Stock and Issue Dividend
2. PhRMA Statement on Department of Homeland Security Efforts to Crack Down on Counterfeiting Crimes
3. Lilly Statement Regarding President Obamas Meeting With U.S. Business Leaders
4. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
5. ERT Files Shelf Registration Statement
6. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
7. Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti
8. Media Statement From Amedisys on Dr. Steven H. Landers NEJM Commentary on the Future of Home Care
9. Statement of Ben Anderson, Esq., Regarding Denial of Wyeths En Banc Petition to Sixth Circuit Court of Appeals in Major Drug Regulation Pre-emption Case
10. Cellectis Publishes Its Financial Statement for the First Half of 2010
11. A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology:
(Date:4/25/2017)... Indianapolis, IN (PRWEB) , ... April 25, 2017 ... ... Washington, D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration ... Life Financial will provide insight into what changes are most likely to make ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in ... to dispensaries and head shops –can’t help but be heartened by the industry’s current ... cannabis odor aptly described as “skunk smell.” At last they can simply, safely ...
(Date:4/25/2017)... ... 25, 2017 , ... There is no better place in South Florida to ... in the May issue of Consumer Reports focused on heart health. , The ... during and after coronary bypass and aortic valve replacement procedures. , Consumer Reports ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
Breaking Medicine News(10 mins):